Biomarkers principles in disease have been applied to cancer detection, screening, diagnosis, treatment, and monitoring. Anti-cancer drugs have traditionally been agents that killed both cancer cells and healthy cells. More targeted therapies, on the other hand, have now been developed that can be directed to kill only cancer cells while leaving healthy cells alone. The evaluation of a common biomarker in cancer aids in the development of therapies that target the biomarkers. This can reduce the risk of toxicity while also lowering treatment costs. Genetic studies are useful in cancer research because genetic abnormalities frequently underpin cancer development. As a result, specific DNA or RNA markers may aid in the detection and treatment of specific cancers.
Read More:
https://ext-6049742.livejournal.com/1088.html
Click here for Biomarkers Market Press Release:
According to research report the global liquid biopsy market is projected to reach USD 2,047.9 million by 2022 from USD 715.7 million in 2017, at a CAGR of 23.4%.
The factors driving the growth of this market are the increasing prevalence of cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancement to augment market revenues, rising emphasis on personalized medicine, and availability of funding for liquid biopsy RGet Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350 Cancers in areas such as the bones, brain, pancreas, or other organs were hard to access with liquid biopsy.
These methods permit the analysis of ctDNA, providing physicians with important biomarker information to take effective therapeutic decisions in almost all cancer areas.
The development of technologically advanced liquid biopsy products is aiding the growth of the market.In this report, the market is segmented on the basis of product, circulating biomarker, clinical application, application, end user, and region.
On the basis of product, the global liquid biopsy market is segmented into assays kits, instruments, and services.
It is also the fastest-growing segment in the products market during the forecast period.Based on circulating biomarkers the market is categorised into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers.
